CE Marking for Dual-Detection Test for Clostridium difficile
By LabMedica International staff writers Posted on 20 Apr 2015 |
CE-IVD approval has been given for a new multiplex test to detection C. difficile infection (CDI) and simultaneous differentiation of the hypervirulence-associated 027 ribotype.
Mobidiag Ltd. (Espoo, Finland) has launched Amplidiag C. difficile+027, a qualitative qPCR-based test performed from DNA extracted from stool in suspected cases of CDI. The CE-marked test, now available throughout Europe, is both economical and well suited to high-volume screening.
In a single reaction, the test offers highly sensitive and specific detection of pathogenic C. difficile by detecting the tcdB (toxin B) gene, and highly accurate differentiation of the hypervirulence-associated 027 ribotype, which has been linked with more severe disease, hospital outbreaks, increased mortality rates, and recurrent infections. The 027 ribotype identification is based on two novel gene markers, whose combination produces very high accuracy in differentiating 027 from other ribotypes. The novel gene markers were identified based on whole-genome sequencing of 88 C. difficile strains.
Performance was evaluated with 309 prospective and 35 spiked samples against toxigenic stool culture findings (the “gold standard”) and through independent molecular methods. Amplidiag C. difficile+027 demonstrated 100% specificity for both tcdB and 027 ribotype, and sensitivities of 97.8% and 94.4% for tcdB and 027 ribotype, respectively.
“Early identification is important for guiding patient management and infection control measures. It is important not only for patient outcome, but also in lowering the overall healthcare costs of CDI. That is why we are very excited to bring this new product to the market,” said Tuomas Tenkanen, CEO of Mobidiag.
Related Links:
Mobidiag
Mobidiag Ltd. (Espoo, Finland) has launched Amplidiag C. difficile+027, a qualitative qPCR-based test performed from DNA extracted from stool in suspected cases of CDI. The CE-marked test, now available throughout Europe, is both economical and well suited to high-volume screening.
In a single reaction, the test offers highly sensitive and specific detection of pathogenic C. difficile by detecting the tcdB (toxin B) gene, and highly accurate differentiation of the hypervirulence-associated 027 ribotype, which has been linked with more severe disease, hospital outbreaks, increased mortality rates, and recurrent infections. The 027 ribotype identification is based on two novel gene markers, whose combination produces very high accuracy in differentiating 027 from other ribotypes. The novel gene markers were identified based on whole-genome sequencing of 88 C. difficile strains.
Performance was evaluated with 309 prospective and 35 spiked samples against toxigenic stool culture findings (the “gold standard”) and through independent molecular methods. Amplidiag C. difficile+027 demonstrated 100% specificity for both tcdB and 027 ribotype, and sensitivities of 97.8% and 94.4% for tcdB and 027 ribotype, respectively.
“Early identification is important for guiding patient management and infection control measures. It is important not only for patient outcome, but also in lowering the overall healthcare costs of CDI. That is why we are very excited to bring this new product to the market,” said Tuomas Tenkanen, CEO of Mobidiag.
Related Links:
Mobidiag
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia